CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Oostindie, Simone C., van der Horst, Hilma J., Lindorfer, Margaret A., Cook, Erika M., Tupitza, Jillian C., Zent, Clive S., Burack, Richard, VanDerMeid, Karl R., Strumane, Kristin, Chamuleau, Martine E. D., Mutis, Tuna, de Jong, Rob N., Schuurman, Janine, Breij, Esther C. W., Beurskens, Frank J., Parren, Paul W. H. I., Taylor, Ronald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717598/
https://www.ncbi.nlm.nih.gov/pubmed/30792198
http://dx.doi.org/10.3324/haematol.2018.207266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717598/
https://www.ncbi.nlm.nih.gov/pubmed/30792198
http://dx.doi.org/10.3324/haematol.2018.207266

Ejemplares similares